Emmaus Life Sciences, Inc.
EMMA · OTC
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.00 | 0.00 | -0.00 | 0.00 |
| FCF Yield | 58.22% | -350.38% | 25.55% | 62.08% |
| EV / EBITDA | 71.48 | -752.01 | -30.74 | -69.97 |
| Quality | ||||
| ROIC | -6.22% | 2.39% | 8.01% | 5.56% |
| Gross Margin | 92.69% | 94.68% | 90.65% | 90.61% |
| Cash Conversion Ratio | -0.20 | 2.56 | -0.12 | -0.20 |
| Growth | ||||
| Revenue 3-Year CAGR | -25.24% | -21.00% | -8.92% | -3.25% |
| Free Cash Flow Growth | 114.06% | -1,142.65% | -17.21% | 126.17% |
| Safety | ||||
| Net Debt / EBITDA | 69.92 | -732.70 | -29.71 | -68.79 |
| Interest Coverage | 0.36 | -0.22 | -0.78 | -0.44 |
| Efficiency | ||||
| Inventory Turnover | 0.20 | 0.11 | 0.16 | 0.19 |
| Cash Conversion Cycle | 511.76 | -1,883.23 | -646.11 | -414.70 |